Latest progress in the development of anti-2019-nCoV therapeutic drugs / 中华临床感染病杂志
Chinese Journal of Clinical Infectious Diseases
;
(6): 103-109, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-957252
ABSTRACT
In recent years, great progress has been made in small molecule therapeutic drugs and monoclonal neutralizing antibody preparations against 2019-nCoV. At least 5 oral drugs (Monupavir, AT-527, Proclutamide, Paxlovid and S-217622) and 2 monoclonal antibodies (Ambavirumab/Romisevirumab combination and Sotrovimab) have completed phase Ⅲ clinical trials exhibiting excellent antiviral effects. This article reviews the research progress of these 7 drugs to provide reference for clinical application.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Clinical Infectious Diseases
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS